GLUE
NASDAQ · Biotechnology
Monte Rosa Therapeutics Inc
$10.57
+0.32 (+3.12%)
Open$10.30
Previous Close$10.25
Day High$10.67
Day Low$9.88
52W High$25.77
52W Low$9.68
Volume—
Avg Volume1.46M
Market Cap901.76M
P/E Ratio—
EPS$-1.74
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+263.8% upside
Current
$10.57
$10.57
Target
$38.45
$38.45
$28.40
$38.45 avg
$50.36
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 130.97M | 401.98M | 400.93M |
| Net Income | -40,909,231 | -29,192,444 | -34,329,564 |
| Profit Margin | -31.2% | -7.3% | -8.6% |
| EBITDA | -48,563,216 | -51,685,540 | -47,809,490 |
| Free Cash Flow | — | -50,874,519 | -44,333,819 |
| Rev Growth | — | +22.8% | -9.2% |
| Debt/Equity | — | 0.43 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $293.30 | +0.68% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $463.45 | +0.66% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $169.25 | +1.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $549.39 | +0.42% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $922.99 | +2.06% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.52 | +0.37% | 7.7 | 20.98B |